PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Approximately 49,200 people are diagnosed with lung cancer every year in the UK. Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma. BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer. J&J’s Darzalex regimen approved by EC for newly diagnosed multiple myeloma.
AstraZeneca’s sipavibart shown to prevent COVID-19 in …
May 16, 2024 · AstraZeneca (AZ) has shared positive results from a late-stage study evaluating the efficacy of its investigational long-acting monoclonal antibody, sipavibart, in preventing COVID-19 in immunocompromised individuals. Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 ...
AbbVie shares promising late-stage results for Parkinson’s disease ...
Oct 7, 2024 · Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder. AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 dopamine receptor partial agonist, tavapadon, as a ...
Results from Global Pharmaceutical Customer Experience survey
Key findings from DT’s latest report, The State Of Customer Experience In The Global Pharmaceutical Industry, 2024: HCP Interactions, include: UCB retains the number one position it gained in 2022 in the overall global CX ranking, with a CXQ score of 65, holding off strong competition from J&J Innovative Medicine and Lilly, which both ...
Pfizer’s Paxlovid given FDA permission to be prescribed by US ...
Jul 7, 2022 · The US Food and Drug Administration (FDA) has revised the Emergency Use Authorisation (EUA) for Paxlovid (nirmatrelvir and ritonavir), authorising pharmacists to prescribe the drug to eligible patients. Under the revision, state-licensed pharmacists will be able to prescribe the drug to patients testing positive for COVID-19, on the condition ...
Merck’s adult-specific pneumococcal vaccine Capvaxive ... - PMLiVE
Jun 19, 2024 · Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for its adult-specific 21-valent pneumococcal conjugate vaccine. Capvaxive is now authorised to prevent invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and older. Diseases caused by ...
2023 PM Society Awards – winners announced - PMLiVE
2023 PM Society Awards – winners announced. The PM Society’s 37th annual awards was held on 17 March 2023 at the JW Marriott Grosvenor House London when the industry came together to celebrate the best creative communications in pharma and healthcare. PM Society Co-Chair Caroline Benson kicked off the afternoon, with charity Duchenne UK ...
PME - Home
A listing of the top 40 creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector. PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to ...
Healthcare - PMLiVE
WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer. Jul 11, 2024 | News, Healthcare. In more than nine out of ten cases, the HPV virus leads to cervical cancer, the fourth most common cancer in women globally. Read More.
Bayer and BlueRock announce positive early-stage results for …
Jun 28, 2023 · Bayer AG and its subsidiary, BlueRock Therapeutics LP, have announced positive topline results from an early-stage study of an experimental Parkinson’s disease stem cell therapy. In the phase 1 study of bemdaneprocel, the treatment was shown to be well-tolerated in all 12 patients involved in the study, and transplanted cells grew as intended ...